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Abstract: EGFr (Epidermal growth factor receptor) overexpression has been detected in many tumors of epithelial origin, 
specifically in breast cancer and it is often associated with tumor growth advantages and poor prognosis. The nimotuzumab is a 
genetically engineered humanized MAb (monoclonal antibody) that recognizes an epitope located in the extracellular domain of 
human EGFr. The aim of this study was to assess the pharmacokinetics of nimotuzumab in patients with locally advanced breast 
cancer who are receiving neoadyuvant therapy combined with the AC chemotherapy regimen (i.e., 60 mg/m2 of Doxorubicin and 600 
mg/m2 of Cyclophosphamide in 4 cycles every 21 days). A single center, non-controlled, open Phase I clinical trial, with 
histopathological diagnosis of locally advanced stage III breast cancer, was conducted in 12 female patients. Three patients were 
enrolled at each of the following fixed dose levels: 50, 100, 200 and 400 mg/week. Multiple intermittent short-term intravenous 
infusions of nimotuzumab were administered weekly, except on weeks 1 and 10, when blood samples were drawn for 
pharmacokinetic assessments. Nimotuzumab showed dose-dependent kinetics. No anti-idiotypic response against nimotuzumab was 
detected in blood samples of participants. There was not interaction between the administration of nimotuzumab and chemotherapy at 
the dose levels studied. The optimal biological doses ranging were estimated to be 200 mg/weekly to 400 mg/weekly.  
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1. Introduction  
The HER (human epidermal growth factor receptor) 
family consists of four tyrosine kinase receptors: 
HER1/ErbB-1 (epidermal growth factor receptor 
(EGFr)), HER2/ErbB-2/ Neu, HER3/ErbB-3 and 
HER4/ErbB-4 [1]. These receptors are highly 
expressed in many solid tumor types, including  
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breast [2], lung [3], ovarian [4], colorectal [5] and 
prostate [6]. They also play an important role in the 
proliferation, differentiation, motility, adhesion, 
protection from apoptosis and transformation of tumor 
cells [1, 7, 8].  
Several strategies have been developed to disrupt 
the EGFr-associated signal transduction cascade. The 
main therapeutic approaches include MAb 
(monoclonal antibodies) [8, 9] directed against the 
extracellular binding domain of the receptor and small 
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molecule tyrosine kinase inhibitors [10], which act by 
interfering with ATP binding to the receptor. 
Nimotuzumab is a humanized monoclonal antibody 
that targets the epidermal growth factor receptor. 
Nimotuzumab, also known as h-R3, is an anti-EGFr 
MAb developed at the Center of Molecular 
Immunology in Havana, Cuba. Originally isolated as a 
murine IgG2a anti-body, known as ior egf/r3, the 
MAb was humanized to reduce its immunogenicity 
and to slow clearance from the body by grafting the 
CDRs (complementarily-determining regions) of R3 
to a human IgG1 gene [11]. In the process, the 
anti-body’s variable fraction was further modified by 
recreating three specific murine amino acids (Ser 75, 
Thr 76, Thr 93) in order to preserve the new MAb’s 
anti-EGFr activity [11]. 
Nimotuzumab is registered as a first-line treatment 
for head and neck cancer in combination with 
radiotherapy [12]. Nimotuzumab is currently being 
evaluated in several clinical trials: two Phase III trials 
as a first-line treatment for pediatric pontine and adult 
glioma, a Phase II/III trial as a treatment for pancreatic 
cancer, the phase II study in colorectal cancer reported 
in this release, phase I in tumors from epithelial origen. 
Some of those results are published already [13-17] 
and some of them are ongoing now. 
The objective of this study was to characterize the 
pharmacokinetic profile of nimotuzumab when given 
in combination with doxorubicin and 
cyclophosphamide in patients treated with cumulative 
dose escalation regimen for each dose and each dose 
level administered, and to determine possible 
dose-dependent changes in the pharmacokinetics of 
nimotuzumab in patients treated with the multiple 
cumulative dose escalation regimen.  
2. Materials and Methods 
2.1 Patient Eligibility 
Patients with histologically confirmed breast locally 
advanced-stage epithelial tumors that were not 
amenable to receive any further therapy and who had 
finished their last treatment at least 4 weeks before 
were included in the trial. Other selection criteria were 
a good performance status, normal hematological 
conditions, as well as normal hepatic and renal 
functions. The most important exclusion criteria 
consisted of previous treatments with murine 
anti-EGFr antibodies, pregnancy or lactation, serious 
chronic diseases, and active infections. All patients 
signed a written consent form before their inclusion in 
the clinical trial. 
2.2 Study Design and Treatment Procedure 
The study was designed as a clinical trial phase I, 
monocenter from scale up, clinical register number 
RPCE00000057 [18]. Twelve patients were included 
in four treatment cohorts, receiving multiple 
administrations of the monoclonal antibody. Three 
patients were enrolled in each of the following fixed 
dose levels: 50, 100, 200 and 400 mg/week. 
Nimotuzumab was administered weekly during 2.5 
months by intravenous infusion of 0.5 hours. Subjects 
were closely monitored during the trial and finished 
the administration of nimotuzumab. The HAMA 
(human anti-mouse antibody) response was evaluated. 
Patients also received a combination of 60 mg/m2 of 
Doxorubicin and 600 mg/m2 of Cyclophosphamide in 
4 cycles every 21 days intercalated with MAb. The 
trial was conducted under the principles outlined in 
the Declaration of Helsinki with the approval of the 
corresponding Ethics Review Committee for human 
subjects protection in clinical trials at the Hermanos 
Ameijeiras Hospital and the State’s Center for Drug 
Quality Control (CECMED), the National Regulatory 
Agency. 
2.3 Pharmacokinetics Assays 
2.3.1 Drug Concentration Measurements 
Serum samples were collected at week 1 and 10th 
immediately before IV infusion and 0, 1, 2, 4, 6, 7 
days following the end of infusion, and before 
administration at 7th day and on every week before 
administration of nimotuzumab until week 9th. 
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Additional samples were collected after 10th 
administration before drug administration on 10th 
doses and 1, 6, 14, 20 and 26 days after the end of 
infusion. Samples were allowed to clot and then 
centrifuged. Serum was collected and stored at -20 °C. 
Serum concentrations of nimotuzumab were 
determined by a receptor-binding, ELISA 
(enzyme-linked immunosorbent assay), using the 
antigen HER 1, recombinant extracellular of EGFr 
domain to capture nimotuzumab from serum samples. 
Bound nimotuzumab was detected with sheep 
antihuman IgG gamma chain specific-alkaline 
phosphate (Sigma Chemical, A-3188, USA), and 
para-nitro-phenyl-phosphate diluted in diethanolamine 
was used as the substrate for color development to 
quantify serum nimotuzumab against a standard curve. 
Absorbance was read at 405 nm. The LLOQ (lower 
limit of quantification) of nimotuzumab in human 
serum was 7.5 ng/mL.  
2.3.2 Pharmacokinetic Analysis  
The individual concentration vs time profiles 
obtained after the first (day 1) and the tenth IV 
infusions (day 10) were analyzed by the NCA 
(non-compartmental analysis) using a combined 
linear/log linear trapezoidal rule approach. 
Pharmacokinetic calculations were performed using 
WinNonlin®, Pharsight® Co., 2006, ver. 5.3.  
A time zero value was considered for extrapolation 
purposes. The linear trapezoidal rule was used up to 
peak level, after which the logarithmic trapezoidal rule 
was applied. Lambda z is a first-order rate constant 
associated with the terminal (log linear) segment of 
the curve. It was estimated by linear regression of the 
terminal data points. The largest adjusted regression 
was selected in order to estimate lambda z, with a 
caveat: if the adjustment did not improve, it was rather 
that within 0.0001 of the largest value the regression 
with larger number of points was used. For each 
patient in each dose level, metrics typically reported in 
pharmacokinetic studies were tabulated. Parameters 
extrapolated to infinity, using the moments of the 
curve, such as AUC (the area under the disposition 
curve), AUMC (the area under the first moment of the 
disposition curve) and MRT (mean residence time) 
were computed based on the last predicted level, 
where the predicted value is based on the linear 
regression performed to estimate terminal lambda 
first-order rate constant. Computing these parameters 
based on the last observed level was discouraged in 
order to avoid larger estimation errors.  
The relationships between estimated pharmacokinetic 
parameters and administered weekly doses were 
assessed in order to determine the threshold level at 
which a dose proportionality is lacked.  
2.4 Statistical Analysis 
Descriptive statistical analyses (i.e., means, 
standard deviations) were performed to summarize the 
pharmacokinetic characteristics of participants in this 
study at each administered dose. Statistical 
comparison between the 1st and 10th administration in 
every dose level (i.e., 50, 100, 200 and 400 mg/week) 
was performed by a non-parametric Kruskal-Wallis 
test. All statistical analyses were performed using the 
SPSS software, version 15.0 (SPSS Inc., Chicago, IL, 
USA, 2006). Statistical significance was set at 5% (P 
< 0.05), with a 95% confidence interval. 
2.5 Anti-Idiotypic Response  
The anti-idiotypic response was evaluated 
pre-treatment, at day 7th and then weekly up to 2 
months. The HAMA (human anti mouse antibody) 
response was considered to be positive when 
post-treatment value/pre-treatment ratio was higher 
than 2. It was determined by an ELISA 
(enzyme-linked immunosorbent assay), using the 
murine ior egf/r3 idiotype (CIMAB, D-0201). Briefly, 
5 µg/mL of ior egf/r3 concentration was used as 
capture system overnight at 4 °C. Plates were washed 
and 1/400 dilutions of serum from 
nimotuzumab-treated patients were added. Plates were 
incubated for 1 hour at 37 °C and washed after adding 
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the antihuman IgG γ chain specific-alkaline phosphate 
conjugated and anti human IgM µ chain 
specific–alkaline phosphate conjugated (Sigma 
Chemical, A-3188 and A-9794, USA, respectively). 
After washing, then a chromogen solution 
(para-nitro-phenil-phosphate 1 mg/mL in 
diethanolamide buffer pH 9.8) was added and 
incubated by 30 min at room temperature. Plates were 
measured on an ELISA reader at 405 nm (Organon 
Teknika, Netherlans) [19].  
3. Results and Analysis 
3.1 Patient Characteristics 
Twelve female patients, mean age 47 (30-63) 
years-old, with a histologically confirmed, advanced 
locally breast tumor were enrolled in the study. 
Participants were recruited from the medical facilities 
at the Hermanos Ameijeiras Hospital in La Habana, 
Cuba. Patient characteristics are detailed in Table 1. 
3.2 Pharmacokinetics 
The corresponding serum drug concentrations-time 
curves for the 1st and 10th administrations of 
nimotuzumab are depicted in Figs. 1 and 2, 
respectively, whereas, the means and standard 
deviations of the pharmacokinetic parameters for the 
first and tenth administration at each dose level are 
shown in Tables 2 and 3, respectively.  
As expected, Fig. 3 shows a typical accumulative 
pattern after multiple doses of nimotuzumab given 
intravenously in each participant by intermittent 
short-term infusions. Besides, that non-proportional, 
greater than anticipated increments in the areas under 
the serum drug concentration-versus-time curves are 
observed across the dose range, which reveals a 
non-linear behaviour.  
The mean AUC0-∞ values increased from 15601.75 
to 71405.05 µg·h/mL after the 1st administrations of 
50 and 400 mg/week, respectively, and from 20677.29 
to 228797.09 µg·h/mL after the corresponding 10th 
administrations of the same dose levels, which 
indicate lack of dose proportionality (Fig. 4a). 
The average value for the elimination half-lives  
(t½) of the humanized MAb in these patients was 
relatively long, and varies from 150.23 hours to 78.02 
hours after the first administration of either 50 
mg/week or 400 mg/week. Accordingly, the average 
drug CL (clearance) was relatively slow for all 
participants. These body weight-normalized CL values 
did not differ significantly along the dose range (i.e., 
oscillating from 0.05 mL/h·kg to 0.11 mL/h·kg), 
except for the 200 mg/week level that increases 
abruptly up to 0.43 mL/h·kg during the first 
administration. However, a decrease in the total 
clearance is observed after the 10th administration 
probably due to a saturation effect (Fig. 4b). 
The average volume of distribution at steady-state 
(Vss) was relatively small, suggesting a limited 
distribution out of the blood compartment or a 
significant binding to plasma/blood components. This 
parameter tends to increase after the 1st administration 
of the 200 mg/week dose level; whereas, these values 
fluctuated after the 10th administration (Fig. 4c). 
When the pharmacokinetic parameters were 
compared across the different dose levels, there were 
found significant differences for AUC0-∞ of 0.019 and 
0.033, Cmax of 0.043 and 0.029 for 1st and 10th 
 
Table 1  Demographic characteristics of the patients. 
Variable All patients (n = 12) 
Gender  
 Female 12 (100%) 
Race  
 White 
 Black 
8 (66.66%) 
4 (33.33%) 
Age (years)  
 Median  
 Average (Range) 
49 
47 (30-63) 
Overall condition as per ECOG  Less 2 
Median (Range) 12 (100%) 
Histology   
Ductal carcinoma 
Lobular carcinoma 
11 (91.66%) 
1 (8.33%) 
Degree of differentiation  
 Intermediate malignancy grade 
High malignancy grade 
Low malignancy grade 
2 (16.66%) 
8 (66.66%) 
2 (16.66%) 
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administration respectively, and CL during the 1st 
administration (0.031), but not for the 10th 
administration indicating the saturation levels of the 
nimotuzumab followed doses multiple regimen 
(Tables 2, 3 and Fig. 4). 
Table 4 presents the estimated average drug 
concentrations at steady state (Cssaverage) and the peak 
and trough steady-state concentrations of nimotuzumab 
for patients in the four different dose levels. The Css 
average values increase disproportionately to the dose 
levels. Indeed, it is observed that at the dose of 200 
mg/week the Css average is almost three times that at 
100 mg/week, which could indicate that a 
dose-dependent non-linearity process is involved in the 
elimination of nimotuzumab.  
3.3 Anti-Idiotypic Response 
After the evaluation of the human response against 
the murine portion of the MAb (using an ELISA test), 
it was verified that the optical density values were in 
all cases very similar to the pre-treatment values for 
the IgM and IgG responses (Fig. 5). 
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Fig. 1  Nimotuzumab mean serum concentration–time profiles in first administration for four doses level. 
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Fig. 2  Nimotuzumab mean serum concentrations–time profiles in tenth administration for the 50, 100, 200 and 400 mg/week 
doses. 
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Table 2  Nimotuzumab pharmacokinetic parameters for the 1st administration. Non-Compartmental Analysis. 
Dose (mg) No. of patients AUC0-∞ (µg·h/mL) Cmax (µg/mL)  t ½ (h) CL/kg (mL/h·kg) Vss/kg (mL/kg) 
50 3 15601.65 ± 5152.58 79.96 ± 22.16 150.23 ± 69.91 0.05 ± 0.01 11.24 ± 2.6 
100 3 11186.87 ± 2105.47 169.67 ± 99.52 63.72 ± 46.32 0.13 ± 0.03 11.25 ± 9.4 
200 3 7879.41 ± 448.75 59.59 ± 4.32 88.66 ± 9.39 0.43 ± 0.04 54.30 ± 8.4 
400 3 71405.05 ± 37116.59 499.53 ± 27.58 78.02 ± 8.78 0.11 ± 0.08 11.93 ± 7.5 
(P)  0.019* 0.043* 0.154 0.031* 0.082 
Values are mean ± SD. AUC0-∞, area under plasma drug concentration-time curve from zero to infinity; Cmax, maximum level of 
concentration; t ½, half-life; CL/kg, clearance corrected per kg of weight; Vss/kg, volume of distribution at steady-state corrected per 
kg of weight. P: Statistical significance < 0.05; IC95: Kruskal-Wallis test. 
 
Table 3  Nimotuzumab pharmacokinetic parameters 10th administration. Non-Compartmental Analysis. 
Dose (mg) No. of patients AUC0-∞ (h·µg/ mL) Cmax (µg/mL)  t ½ (h) CL/kg (mL/h·kg) Vss/kg (mL/kg) 
50 3 20677.29± 6881.28 73.98 ± 11.72 274.20 ± 66.59 0.04 ± 0.02 16.00 ± 4.94 
100 3 25489.90 ± 10656.01 64.58 ± 57.06 355.62 ± 145.01 0.06 ± 0.03 33.07 ± 22.7 
200 3 71765.77 ± 35480.68 257.63 ± 106.9 218.62 ± 5.08 0.05 ± 0.02 17.91 ± 8.38 
400 3 228797.09 ± 228232.98 582.4 ± 325.31 105.76 ± 19.76 0.08 ± 0.07 11.47 ± 10.7 
(P)  0.033* 0.029* 0.082 0.705 0.459 
Values are mean ± SD. AUC0-∞, area under plasma drug concentration-time curve from zero to infinity; Cmax, maximum level of 
concentration; t ½, half-life; CL/kg, clearance corrected per kg of weight; Vss/kg, volume of distribution at steady-state corrected per 
kg of weight. P: Statistical significance < 0.05, IC95: Kruskal-Wallis test. 
 
 
Fig. 3  Nimotuzumab concentration-time data in multiple administration regime. Graph shows the observed nimotuzumab 
concentrations represented as symbols and color lines with black rhombus, blue square, red rhombus and green triangle for 
the 50, 100, 200 and 400 mg/week doses, respectively. 
 
Once the post-treatment/pre-treatment ratio of ³ 2 
was established as the cohort value to consider if a 
patient would have a positive anti-idiotypical response, 
it was confirmed that none of the patients treated had a 
higher value. Therefore, it can be considered that with 
10 doses of the MAb, even after the single dose was 
increased to 400 mg/week and the total dose being 
4000 mg, the patients did not develop a response 
against the murine portion of the nimotuzumab, which 
shows low immunogenicity of this MAb due to its 
humanized characteristics. See Fig. 5 for anti-idiotypic 
response, anti-IgG and anti-IgM graphs. 
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(a) 
 
(b) 
 
(c) 
Fig. 4  a, Area under the serum concentration time curve from time zero to infinity (AUC0-∞) as a function of the 
nimotuzumab dose from 50 to 400 mg/week (n = 12); b, CL/kg (Clearance corrected per kg of weight) as a function of the 
nimotuzumab dose from 50 to 400 mg/week (n = 12); c, Vss/kg (volume of distribution at steady-state corrected per kg of 
weight) as a function of the nimotuzumab dose from 50 to 400 mg/week (n = 12).  
 
Table 4  Estimates average concentration in the steady state and maximal and minimal concentration in the steady state of 
Nimotuzumab. 
Dose (mg) No. of patients Cssaverage Cssmax Cssmin 
50 3 122.53 ± 38.27 149.39 ± 44.0 98.76 ± 33.02 
100 3 160.57 ± 63.51 196.26 ± 93.75 129.93 ± 41.83 
200 3 465.6 ± 290.37 592.53 ± 369.52 357.89 ± 223.19 
400 3 864.72 ± 550.40 1379.27 ± 869.70 498.67 ± 333.47 
Values are mean ± SD. Cssaverage: estimates average concentration in the steady state; Cssmax: maximum concentration in the steady 
state; Cssmin: minimum concentration in the steady state.  
AUC0-∞ 
 
Pharmacokinetics Evaluation of Nimotuzumab in Combination with Doxorubicin and Cyclophosphamide in 
Patients with Advanced Breast Cancer 
  
1130
    
 
    
Fig. 5  Anti-idiotypic response in treated patients (n = 12). 
 
4. Discussion 
Despite the advances in surgery, radiation and 
chemotherapy, advanced epithelial-derived cancer 
largely represent an unsolved problem. Today, 
biologic therapy emerges as the fourth modality for 
cancer management, being a very attractive option 
taking into consideration its specificity and low 
toxicity [20]. Passive immunotherapy against solid 
tumors with naked antibodies has recently 
demonstrated efficacy in the clinical setting [20]. 
EGFr is a very attractive target for immunotherapy 
since EGFr driven autocrine growth pathway has been 
implicated in the development and progression of the 
majority of human epithelial cancers [21]. 
Breast cancer shows an increase in the EGFr 
expression, and  it  has  been  reported  that  14-91%  
of tumours over-express this receptor [2]. The action 
of nimotuzumab plus AC chemotherapy was 
evaluated in this  study.  Given  the  fact  that  
nimotuzumab competitively inhibits the binding of the 
EGF ligand to the extracellular domain of the HER-1 
protein, leading to a further inhibition of the 
homodimerization or heterodimerization of this 
receptor and subsequent autophosphorylation of its 
tyrosine residues, the activation of the different 
ligand-induced signal transduction pathways 
(Ras-Raf-MEK-MAPKS cascade; PI3K) will be 
inhibited as well [10]. The aim was to assess the 
pharmacokinetic of nimotuzumab in patients with 
locally advanced breast cancer who are receiving 
neoadyuvant therapy combined with the AC 
chemotherapy regimen. Moreover, AC acts directly on 
the nucleus of the cells that are in turnover phase and 
therefore the replication of the DNA would be 
inhibited and the combination of both therapeutic 
agents potentiates the antitumour effect (Fig. 3).  
Cetuximab (chimeric monoclonal anti-EGFR 
antibody) combined with antineoplastic agents 
showed a synergistic effect and an increase in the 
anti-tumour efficacy in metastatic colorectal cancer 
and head and neck tumors [22]. It is suggested that the 
MAb Erbitux presents synergistic activity with many 
antineoplastic agents such as cisplatin, doxorubicin, 
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paclitaxel and irinotecan [22]. 
Trastuzumab, a humanized MAb that recognizes the 
HER-2 receptor (a member of the EGFr family) was 
licensed in 1997 for the treatment of metastatic breast 
cancer combined with paclitaxel [23]. Different 
clinical studies have led to an extension of this therapy 
to the earlier stages of breast cancer, based on the fact 
that this molecule blocks HER2, which is part of the 
EGFr group [23].  
Nimotuzumab was combined with an anthracycline 
based chemotherapy (i.e., doxorubicin-cyclophosphamide) 
in the phase I clinical study. This new therapeutic 
regimen for nimotuzumab included an increase in the 
number of administrations up to ten doses. The first 
dose of this MAb was administered before starting 
chemotherapy in order to induce an effect of 
nimotuzumab on a HER 1 over-expressing tumour 
without any interference of the cytostatic therapy as 
well as to assess the pharmacokinetics of nimotuzumab 
in this type of patient and therapy.  
To our knowledge, this is the first time a 
pharmacokinetic report on Nimotuzumab combined 
with chemotherapy after multiple dosing in breast 
cancer patients is written. The pharmacokinetic 
analyses for nimotuzumab showed a lack of dose 
proportionality within the dose range of 50-400 mg 
weekly, as suggested by a disproportional increase of 
AUC0-∞ over the entire dose range and dose-dependent 
clearance and apparent distribution volumes. This is 
typically the non-linear pharmacokinetic behavior that 
has been early reported for other monoclonal 
antibodies in humans [13, 22, 23].  
Clearance variations observed over the entire dose 
range and the resulting dose-dependency pattern in 
this study was opposed to some previous reports for 
this (i.e., I125-labelled nimotuzumab) and other MAbs 
[13, 22, 23]. However, the results of the current study 
correlate well with an early report from a 
pharmacokinetic study of nimotuzumab in patients 
with locally advanced or metastatic pancreatic cancer 
that was conducted in Germany [24].  
Although no statistically significant differences are 
found between clearance values of this MAb after the 
10th administration (Table 3), results after the 1st 
administration (Table 2) showed a slight but 
significant variation of the MAb clearance in these 
patients (P = 0.03), with total clearance rising steadily 
up to the dose of 200 mg/week and then a sudden 
decrease is observed at the 400 mg/week dose. Since 
there is a turning point in the total systemic clearance 
of nimotuzumab at the interval of 200 mg/week to 400 
mg/week, we consider this dose range as one 
representing a saturation region for its biological 
targets or reservoirs in the body and thus a potential 
optimal dose level. An explanation for the clearance 
variations observed in the dose range (i.e., 50-200 
mg/week) tested in this study cohort could be found in 
the additive nature of this parameter: CL Total = 
specific CL + non-specific CL [25]. 
We speculate that the total systemic clearance 
reduction at the very high dose is probably a 
consequence of the saturation of the membrane-bound 
EGFr-mediated elimination pathway (i.e., a specific 
clearance routes with limited capacity such as 
receptor-mediated endocytosis). The impact of the 
antigen/target on the non-linear pharmacokinetics of 
MAbs is generally characterized by faster clearance 
rates at a lower dose range; whereas, the clearance 
decreases at the highest dose of the antibody due to a 
saturation of the specific antigen/target-mediated 
clearance process. However, non-specific processes 
(e.g., RES (reticule-endothelial system)-mediated 
events) are likely favoured at increasing doses [25] and, 
therefore, they might account for most of the observed 
changes in clearance at the studied dose range. 
On the other hand, the systemic clearance of MAbs 
in cancer patients could be modified by several factors 
including soluble antigen in circulation and 
immunogenicity [25]. For instance, previous reports 
from a phase I clinical trial study revealed an increased 
clearance of trastuzumab, which was associated with 
high levels of shed antigen [23]. In another study of 
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nimotuzumab given to 12 patients with advanced 
epithelial-derived cancer, Crombet et al. observed that 
3 patients with ductal infiltrating breast carcinomas 
had positive serum elevation of shedding EGFr [13]. 
Since we have patients with advanced breast cancer in 
our study cohort, we believe that a fraction of the 
nimotuzumab in the bloodstream is bound to these 
circulating antigens, and that nonspecific RES 
clearance process [25] is also contributing to the 
increasing clearance value observed across the dose 
ranges from (50 mg/week to 200 mg/week). In fact, it 
seems to be that EGFr shedding correlated with 
nimotuzumab clearance after the 1st administration. 
Increased serum ECD (Extracellular Domain) levels 
of EGFr have been early reported in patients with 
cancers that are known to overexpress Her 1 or Her 2 
protein [23, 26, 27]. In a study with patients suffering 
from metastatic breast cancer who were receiving 2 
mg/kg of trastuzumab, a patient with high circulating 
shed antigens had a similar reduction of serum 
concentrations to that observed in our study after 
giving the dose of 200 mg/week during the 1st 
administration [23]. This report suggests that high 
circulating antigens will decrease the elimination 
half-life and the trough serum concentrations of 
humanized MAb against HER2 product [23]. Besides, 
high serum concentrations of HER 2 ECD have been 
correlated with higher relapse rates, and elevated 
pretreatment levels of HER2 ECD have also been 
associated with poor clinical response to hormone 
therapy and chemotherapy in metastatic breast cancer 
patients [27]. Therefore, monitoring of circulating 
shed antigen level is considered to be essential in 
trastuzumab therapy [27]. 
Notably, these shed EGFr molecules do not seem to 
significantly interfere with the clearance of 
nimotuzumab after the 10th administration cycle. It 
might be due to a depletion of circulating antigens 
after multiple administrations of the MAb.  
The human anti-murine antibody response does not 
alter the clearance of nimotuzumab. The lack of 
anti-idiotypic response in this study emphasizes the 
relatively non-immunogenicity of this humanized MAb 
following repeated administrations of nimotuzumab the 
doses. In previous studies by Crombet et al., the 
anti-idiotypic antibodies were not detected in any 
patient after IV infusions of nimotuzumab at several 
dose levels, with measurements performed up to 6 
months after treatment [13]. 
A limitation of our study is the relatively small 
sample size to perform the corresponding statistical 
analyses with power enough to draw valid conclusions. 
Accordingly, results and recommendations should be 
observed with cautions. 
5. Conclusion 
Nimotuzumab showed a non-linear dose-dependent 
pharmacokinetics. No interactions between the 
administration of nimotuzumab and chemotherapy 
(doxorubicin plus cyclophosphamide) were observed 
at the studied dose levels. No anti-idiotypic response 
to nimotuzumab was found in the patients enrolled in 
this study. Monitoring of circulating shed EGFr level 
must be considered in nimotuzumab therapy for breast 
cancer. Based on our findings, we preliminarily 
recommend the 200 mg/week to 400 mg/week 
infusion dose range as the OBD (Optimal Biological 
Dose) range to be proposed for further human studies 
of this MAb. 
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